Description: Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, HIV, respiratory, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. It also provides respiratory products, including inhalers and nasal sprays, as well as other dosage forms consists of injectables and biosimilars. The company has collaboration with CSIR-Indian Institute of Chemical Technology for the development of medication for the treatment of COVID-19. Cipla Limited was founded in 1935 and is headquartered in Mumbai, India.
Exchange: BSE
Country: IN
Currency: Indian Rupee (INR)
| Forward PE: | 21.5054 |
|---|---|
| Trailing PE: | 51.3486 |
| Price-to-Book MRQ: | 4.0842 |
| Price-to-Sales TTM: | 4.1117 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 25845 |